

DOCKET NO: 295010US40PCT

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF :
AKIHIRO TAKEMIYA, ET AL. : EXAMINER: CHANG, CELIA C.
SERIAL NO: 10/589,130 :
FILED: JANUARY 16, 2007 : GROUP ART UNIT: 1625
FOR: INDAZOLE COMPOUND AND :
PHARMACEUTICAL USE THEROF

RESPONSE TO THE REQUIREMENT FOR RESTRICTION

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

In response to the Restriction Requirement mailed February 19, 2010, Applicants elect, with traverse, Group I: Claims 7-9 drawn to indazole compounds where R2 is piperidine compounds. Applicants have also elected as the species the compound of Example 130 on page 115 of the specification: 4-(2-fluoro-5-methylphenyl)-4-hydroxy-1-piperidinecarboxylic acid (1H-indazol-3-yl)amide.

Applicants request that the Examiner expand the search to the non-elected claims of Groups II-IV, Claims 1-6 and 10-12, if the elected Group I claims are found allowable.

Remarks begin on page 2 of this paper.